Welltower Inc.
WELLWelltower Inc. is coiled. The quarters are improving, yet the P/E sits at the 34th percentile of its own 4-year range — the business is moving before the market.
The sharpest disagreement: the price moved +39.3% in a year while annual EPS moved −11.5% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (152 weeks in) while the P/E sits at the 34th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +188.5% year on year, and 294% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Welltower Inc. trades at $232, in a confirmed uptrend and 152 weeks into that stage. That is +13.1% against its own 200-day average. It sits at 77% of a 52-week range of $163 to $252. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks.
Today the stock is in a confirmed uptrend — week 152 of stage 2. At $232 it trades +13.1% versus its 200-day average and sits at 77% of its 52-week range ($163–$252).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +206% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Welltower Inc. trades at 105.7× P/E, near the bottom of its own range — cheaper only 34% of the time. Its long-run median P/E is 121.8×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 105.7× is near the bottom of its own range — cheaper only 34% of the time, against a long-run median of 121.8× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −11.5% against a +39.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +41.1%/yr price move, ~+106.3%/yr came from earnings growth and ~−65.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Welltower Inc. reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +253.8% at its peak to +31.8% but is still expanding, ROCE holding at 0.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +35.7% | +22.8% | — | — |
| Profit | −1.0% | +81.7% | — | — |
| EPS | −11.5% | +66.7% | — | — |
| Stock price | +39.3% | +41.1% | +22.1% | +11.7% |
4-Factor Sector Score
49.5/100 — rank 5 of 17 in REIT - Healthcare Facilities · 60% evidence confidence
Welltower Inc. scores 49.5 out of 100 against the 17 companies it is compared with in REIT - Healthcare Facilities, ranking 5. Price leads the evidence: RS versus the benchmark is 4.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 16.9 + 10.8 + 4.3 + 17.5 = 49.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Welltower Inc. reported $3.4 B of revenue in the Mar 26 quarter, +38.4% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 23.0% a year. The last full year, FY25, came in at $10.8 B. The last four reported quarters add to $11.8 B.
FY25 revenue came in at $10.8 B (+35.7% on the year), capping 4 years at 23.0% compound. The latest quarter (Mar 26) printed $3.4 B, +38.4% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +37.6% growth against the decade's 23.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +37.7% over the last 4 quarters against +30.2%/yr over the last 8 — accelerating; TTM profit +31.8% vs +77.5%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Welltower Inc.'s operating margin is 16.1% in the Mar 26 quarter, +1.6 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.8% to 14.8%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 16.1%, +1.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.8%–14.8%.
Why the margin moved: operating margin went +1.6 pp year on year while gross margin went −0.9 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Welltower Inc. earned $0.8 B of net profit in the Mar 26 quarter, +188.5% year on year. Full-year FY25 profit was $1.0 B. The 4-year compound rate is 26.9%. That is 22.4% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.
Mar 26 profit was $0.8 B, +188.5% year on year. On the full year, FY25 printed $1.0 B (−1.0%), and the 4-year compound rate is 26.9%.
Why profit moved: revenue contributed +38.4% and the margin +1.6 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +41.2% vs revenue +37.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 294% of Welltower Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.9 B of operating cash against $1.0 B of profit. After $1.5 B of capital spending, $1.4 B was left as free cash.
FY25: operating cash of $2.9 B against reported profit of $1.0 B, leaving free cash of $1.4 B after $1.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 294% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Welltower Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $5.0 B over the last 3 years. Averaged over those years that is 15.4% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $5.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Welltower Inc. earns a ROE of 2% in FY25. That is up from a trough of 1% in FY22. Return on invested capital clears the cost of that capital by −6.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.9% net margin on 0.16× asset turns.
FY25 ROE is 2%, recovered from a FY22 trough of 1% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY25): 8.9% net margin × 0.16× asset turns × 1.56× balance-sheet leverage ≈ 2.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 1.3% − 7.9% = a −6.6 pp spread. The 7.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Welltower Inc. paid $2.96 per share over the last four reported quarters, up 10.4% on a year ago. The most recent declaration was $0.74 for Mar 26. Against the current price of $232 that is a trailing yield of 1.28%, measured on dividends already paid rather than on a forecast.
Welltower Inc. paid $2.96 per share across the last four reported quarters, most recently $0.74 for Mar 26. That is up 10.4% against the same quarter a year earlier. Against the current price of $232 the trailing twelve months work out to 1.28% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Welltower Inc. carries total debt of $19.7 B against shareholder equity of $47.7 B as of Jun 26, a debt-to-equity of 0.41. On the annual view that ratio went from 0.77 in FY21 to 0.49 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $19.7 B against shareholder equity of $47.7 B — a debt-to-equity of 0.41. On the annual view, debt-to-equity went from 0.77 (FY21) to 0.49 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
2.6% of Welltower Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 5.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 2.6% of the float is sold short, and at typical trading volumes it would take about 5.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Welltower Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Strawberry Fields REIT, Inc.STRW | 59.2/100Mixed-positive evidence70% evidence | TURNING | 19.7/35 Income 26.4% · PAT 28.6% 71% evidence | 20.4/25 ROA 2.6% · ROE 37.4% · GNPA — 68% evidence | 7.8/20 P/BV 13.04× · P/BV÷ROE 0.35 70% evidence | 11.3/20 RS sector 0.6% · RS bench -0.2% · 1Y 33.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 19.7 + 20.4 + 7.8 + 11.3 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Omega Healthcare Investors, Inc.OHI | 54.3/100Mixed-positive evidence60% evidence | ASLEEP | 20.3/35 Income — · PAT — 26% evidence | 17.5/25 ROA 1.8% · ROE 7% · GNPA — 68% evidence | 8.0/20 P/BV 2.65× · P/BV÷ROE 0.38 70% evidence | 8.5/20 RS sector -2.3% · RS bench -3.2% · 1Y 22%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 17.5 + 8 + 8.5 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3LTC Properties, Inc.LTC | 54.2/100Mixed-positive evidence76% evidence | BASING | 26.3/35 Income 53.3% · PAT 39.1% 71% evidence | 15.7/25 ROA 1.8% · ROE 2.1% · GNPA — 68% evidence | 7.6/20 P/BV 1.67× · P/BV÷ROE 0.79 70% evidence | 4.6/20 RS sector -6.4% · RS bench -7.2% · 1Y 7.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.7 + 7.6 + 4.6 = 54.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -6.4% and the one-year return is 7.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 4CareTrust REIT, Inc.CTRE | 52.7/100Mixed-positive evidence76% evidence | ASLEEP | 22.8/35 Income 58.2% · PAT 100% 71% evidence | 16.5/25 ROA 2% · ROE 2.2% · GNPA — 68% evidence | 6.9/20 P/BV 2.01× · P/BV÷ROE 0.91 70% evidence | 6.5/20 RS sector -2.1% · RS bench -3% · 1Y 24.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.8 + 16.5 + 6.9 + 6.5 = 52.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -2.1% and the one-year return is 24.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 5Welltower Inc.this pageWELL | 49.5/100Mixed-negative evidence60% evidence | BREAKING OUT | 16.9/35 Income — · PAT — 26% evidence | 10.8/25 ROA 0.9% · ROE 1.1% · GNPA — 68% evidence | 4.3/20 P/BV 3.52× · P/BV÷ROE 3.2 70% evidence | 17.5/20 RS sector 5.9% · RS bench 4.8% · 1Y 37.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 10.8 + 4.3 + 17.5 = 49.5 · Decision use: Price leads the evidence: RS versus the benchmark is 4.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Universal Health Realty Income TrustUHT | 47.5/100Mixed-negative evidence60% evidence | BASING | 18.7/35 Income — · PAT — 26% evidence | 15.9/25 ROA 1.6% · ROE 3.8% · GNPA — 68% evidence | 5.5/20 P/BV 4.23× · P/BV÷ROE 1.11 70% evidence | 7.4/20 RS sector -6.4% · RS bench -7.2% · 1Y 9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 15.9 + 5.5 + 7.4 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Healthpeak Properties, Inc.DOC | 47.0/100Mixed-negative evidence76% evidence | BREAKING OUT | 10.5/35 Income 2.7% · PAT -18.2% 71% evidence | 9.4/25 ROA 0.4% · ROE 2.2% · GNPA — 68% evidence | 7.9/20 P/BV 1.46× · P/BV÷ROE 0.66 70% evidence | 19.2/20 RS sector 6.9% · RS bench 6.1% · 1Y 27.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.5 + 9.4 + 7.9 + 19.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 6.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 8National Health Investors, Inc.NHI | 45.6/100Mixed-negative evidence76% evidence | BASING | 17.6/35 Income 17.2% · PAT 5% 71% evidence | 16.8/25 ROA 1.8% · ROE 2.7% · GNPA — 68% evidence | 6.4/20 P/BV 2.59× · P/BV÷ROE 0.96 70% evidence | 4.8/20 RS sector -14.3% · RS bench -15% · 1Y -0.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.8 + 6.4 + 4.8 = 45.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Ventas, Inc.VTR | 45.4/100Mixed-negative evidence60% evidence | ASLEEP | 19.4/35 Income — · PAT — 26% evidence | 10.2/25 ROA 1.1% · ROE 0.5% · GNPA — 68% evidence | 3.4/20 P/BV 3.11× · P/BV÷ROE 6.22 70% evidence | 12.4/20 RS sector 2.4% · RS bench 1.4% · 1Y 32.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 10.2 + 3.4 + 12.4 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10American Healthcare REIT, Inc.AHR | 44.3/100Mixed-negative evidence67% evidence | TURNING | 18.1/35 Income 12.2% · PAT — 45% evidence | 8.4/25 ROA 0.8% · ROE 0.8% · GNPA — 68% evidence | 4.4/20 P/BV 2.57× · P/BV÷ROE 3.22 70% evidence | 13.4/20 RS sector 2.4% · RS bench 1.4% · 1Y 34.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 8.4 + 4.4 + 13.4 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Diversified Healthcare TrustDHC | 43.9/100Thin evidence · provisional55% evidence | FADING | 15.8/35 Income 0.4% · PAT — 45% evidence | 4.3/25 ROA -0.1% · ROE -2.4% · GNPA — 68% evidence | 9.8/20 P/BV 0.99× · P/BV÷ROE — 10% evidence | 14.0/20 RS sector 28% · RS bench 26.1% · 1Y 161.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 4.3 + 9.8 + 14 = 43.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Sila Realty Trust, Inc.SILA | 43.7/100Mixed-negative evidence70% evidence | 15.4/35 Income 9.7% · PAT -71.4% 71% evidence | 9.2/25 ROA 1% · ROE 0.3% · GNPA — 68% evidence | 4.1/20 P/BV 0.98× · P/BV÷ROE 3.27 70% evidence | 15.0/20 RS sector 2.8% · RS bench 8.8% · 1Y 26.4%7 of 7 weeks ahead to 2026-07-02 70% evidence | |
| Exact sum: 15.4 + 9.2 + 4.1 + 15 = 43.7 · Decision use: Price leads the evidence: RS versus the benchmark is 8.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 13Sabra Health Care REIT, Inc.SBRA | 42.4/100Mixed-negative evidence76% evidence | BASING | 18.0/35 Income 12.9% · PAT 11.3% 71% evidence | 11.7/25 ROA 1.1% · ROE 1.5% · GNPA — 68% evidence | 5.9/20 P/BV 1.74× · P/BV÷ROE 1.16 70% evidence | 6.8/20 RS sector -3.8% · RS bench -4.7% · 1Y 10.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.7 + 5.9 + 6.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Community Healthcare Trust IncorporatedCHCT | 39.6/100Mixed-negative evidence61% evidence | ASLEEP | 16.4/35 Income 5.1% · PAT — 45% evidence | 9.4/25 ROA 0.9% · ROE 0.6% · GNPA — 68% evidence | 5.5/20 P/BV 1.08× · P/BV÷ROE 1.8 70% evidence | 8.3/20 RS sector -2.1% · RS bench -3% · 1Y 22.6%1 of 12 weeks ahead 70% evidence |
| Exact sum: 16.4 + 9.4 + 5.5 + 8.3 = 39.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Medical Properties Trust, Inc.MPT | 27.8/100Adverse evidence67% evidence | BASING | 14.5/35 Income 5.4% · PAT — 45% evidence | 5.8/25 ROA -93.4% · ROE 0.7% · GNPA — 68% evidence | 7.2/20 P/BV 0.61× · P/BV÷ROE 0.87 70% evidence | 0.3/20 RS sector -16.1% · RS bench -16.7% · 1Y 14%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 5.8 + 7.2 + 0.3 = 27.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Chiron Real Estate Inc.XRN | 26.7/100Adverse evidence70% evidence | BASING | 9.9/35 Income 9.4% · PAT -200% 71% evidence | 7.5/25 ROA 0.7% · ROE 0.3% · GNPA — 68% evidence | 5.2/20 P/BV 0.88× · P/BV÷ROE 2.92 70% evidence | 4.1/20 RS sector -8.9% · RS bench -9.6% · 1Y 6.9%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.9 + 7.5 + 5.2 + 4.1 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Healthcare Realty Trust IncorporatedHR | 44.1/100Thin evidence · provisional48% evidence | FADING | 20.4/35 Income — · PAT — 26% evidence | 5.2/25 ROA 0.4% · ROE -1% · GNPA — 68% evidence | 9.8/20 P/BV 1.64× · P/BV÷ROE — 10% evidence | 8.7/20 RS sector -0.4% · RS bench -1.2% · 1Y 21.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 5.2 + 9.8 + 8.7 = 44.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Welltower Inc.'s stock price today?
Welltower Inc. trades at $232, +39.3% over the past year. The company is valued at $167 B. The stock sits at 77% of its 52-week range of $163–$252, +13.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 152 weeks in. — as of 5 August 2026.
What were Welltower Inc.'s latest quarterly results?
Welltower Inc. reported revenue of $3.4 B and net profit of $0.8 B for the Mar 26 quarter. Revenue rose 38.4% and profit rose 188.5% year on year. Earnings per share were $1.02. The operating margin was 16.1%, 1.6 pp higher than a year earlier. — as of 5 August 2026.
What is Welltower Inc.'s revenue?
Welltower Inc. reported revenue of $3.4 B in the Mar 26 quarter, +38.4% year on year. For the full FY25 fiscal year, revenue was $10.8 B (+35.7%). Over the last 4 years revenue compounded at 23.0% a year. — as of 5 August 2026.
What is Welltower Inc.'s profit?
Welltower Inc. earned $0.8 B of net profit in the Mar 26 quarter, +188.5% year on year. Full-year FY25 profit was $1.0 B. The operating margin ran 16.1% in the latest quarter. — as of 5 August 2026.
What is Welltower Inc.'s market cap?
Welltower Inc.'s market capitalisation is $167 B at a stock price of $232. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Welltower Inc.'s P/E ratio?
Welltower Inc. trades at a P/E of 105.7×, at the 34th percentile of its own 4-year range, against a long-run median of 121.8×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Welltower Inc. pay a dividend?
Yes — Welltower Inc. declared $0.74 per share for Mar 26, and $2.96 per share across the last four reported quarters. The latest quarter is up 10.4% on the same quarter a year earlier. — as of 5 August 2026.
What is Welltower Inc.'s dividend per share?
Welltower Inc.'s most recently declared dividend is $0.74 per share for Mar 26, giving $2.96 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Welltower Inc.'s dividend yield?
Welltower Inc.'s trailing dividend yield is 1.28%: $2.96 declared per share across the last four reported quarters, against a share price of $232. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Welltower Inc. overvalued?
On its own history, Welltower Inc. looks cheap against its own history: its P/E of 105.7× has been cheaper only 34% of the time in 4 years (long-run median 121.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Welltower Inc. growing?
Yes — Welltower Inc. is growing: latest-quarter revenue +38.4% year on year, profit +188.5%, and the margin +1.6 pp at 16.1%. The 4-year compound rates are 23.0% (revenue) and 26.9% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Welltower Inc. performing?
Welltower Inc. is in a confirmed uptrend, 152 weeks in. Its latest quarter's revenue rose 38.4% and profit rose 188.5% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Welltower Inc. in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +253.8% at its peak to +31.8% but is still expanding, ROCE holding at 0.7%. The read comes from the last 12 quarters of growth (revenue growth +37.7% latest, profit growth +31.8% latest, eps growth +16.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Welltower Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 152 of stage 2), trading +13.1% versus its 200-day average and at 77% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Welltower Inc. beating the market?
On recent form, yes — Welltower Inc. has been ahead of the S&P 500 on a trailing-13-week view for 7 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +206% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.
Will Welltower Inc.'s stock price go up?
This page publishes no price forecast for Welltower Inc. What it measures instead: the stock price is $232, the price is in a confirmed uptrend 152 weeks in. Its P/E of 105.7× sits at the 34th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Welltower Inc.?
Somewhat — short interest is 2.6% of Welltower Inc.'s tradable float, about 5.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Welltower Inc. have too much debt?
It is moderate — Welltower Inc.'s debt-to-equity is 0.41. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Welltower Inc.'s capex?
Welltower Inc. spent $5.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.5 B. — as of 5 August 2026.
What is Welltower Inc.'s cash flow?
Welltower Inc. generated $2.9 B of operating cash flow in FY25 and $1.4 B of free cash flow after $1.5 B of capital spending. Reported profit that year was $1.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Welltower Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 294% of Welltower Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $2.9 B against reported profit of $1.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
Where is Welltower Inc. in its business cycle?
Welltower Inc.'s FY25 operating margin was 1.8%, against a 5-year band of 1.8%–14.8%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 16.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Welltower Inc. story?
The sharpest disagreement: the price moved +39.3% in a year while annual EPS moved −11.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Welltower Inc. a stock worth studying right now?
This is not investment advice. The machine read: Welltower Inc. is coiled. The quarters are improving, yet the P/E sits at the 34th percentile of its own 4-year range — the business is moving before the market. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.